Trial Outcomes & Findings for Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation (NCT NCT01813110)

NCT ID: NCT01813110

Last Updated: 2023-08-21

Results Overview

Change in blood levels of CRP at 24 hours post endotoxin administration, after each 8 week intervention

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

21 participants

Primary outcome timeframe

24 hours post endotoxin administration, following each 8 week intervention

Results posted on

2023-08-21

Participant Flow

A balanced randomization scheme was developed in advance, and subjects were assigned to a treatment sequence at enrollment.

Participant milestones

Participant milestones
Measure
Placebo (8 Weeks), Then Omega-3 Fatty Acids (8 Weeks)
8 weeks of placebo (olive oil) supplementation followed by 8 weeks of omega-3 fatty acid supplementation (4 g prescription omega-3 fatty acid concentrate)
Omega-3 Fatty Acids (8 Weeks), Then Placebo (8 Weeks)
8 weeks of omega-3 fatty acid supplementation (4 g prescription omega-3 fatty acid concentrate) followed by 8 weeks of placebo (olive oil) supplementation
Overall Study
STARTED
10
11
Overall Study
COMPLETED
10
10
Overall Study
NOT COMPLETED
0
1

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Baseline
n=20 Participants
Baseline (prior to placebo or omega-3 supplementation)
Age, Continuous
27 years
STANDARD_DEVIATION 1 • n=99 Participants
Sex: Female, Male
Female
0 Participants
n=99 Participants
Sex: Female, Male
Male
20 Participants
n=99 Participants

PRIMARY outcome

Timeframe: 24 hours post endotoxin administration, following each 8 week intervention

Change in blood levels of CRP at 24 hours post endotoxin administration, after each 8 week intervention

Outcome measures

Outcome measures
Measure
Placebo (8 Weeks)
n=20 Participants
8 weeks of placebo (olive oil) supplementation prior to low-dose endotoxin challenge
Omega-3 Fatty Acids (8 Weeks)
n=20 Participants
8 weeks of omega-3 fatty acid supplementation (4 g prescription omega-3 fatty acid concentrate) prior to low-dose endotoxin challenge
Change in C Reactive Protein (CRP)
17.2 mg/L
Standard Error 1.8
17.1 mg/L
Standard Error 1.8

SECONDARY outcome

Timeframe: 2 hours post endotoxin administration, following each 8 week intervention

Change in the plasma concentration of TNF-α at 2 hours post endotoxin administration, after each 8 week intervention

Outcome measures

Outcome measures
Measure
Placebo (8 Weeks)
n=20 Participants
8 weeks of placebo (olive oil) supplementation prior to low-dose endotoxin challenge
Omega-3 Fatty Acids (8 Weeks)
n=20 Participants
8 weeks of omega-3 fatty acid supplementation (4 g prescription omega-3 fatty acid concentrate) prior to low-dose endotoxin challenge
Tumor Necrosis Factor-α (TNF-α)
58.3 pg/mL
Standard Error 8.1
59.9 pg/mL
Standard Error 8.1

SECONDARY outcome

Timeframe: 2 hours post endotoxin administration, following each 8 week intervention

Change in the plasma concentration of TNF-α at 2 hours post endotoxin administration, after each 8 week intervention

Outcome measures

Outcome measures
Measure
Placebo (8 Weeks)
n=20 Participants
8 weeks of placebo (olive oil) supplementation prior to low-dose endotoxin challenge
Omega-3 Fatty Acids (8 Weeks)
n=20 Participants
8 weeks of omega-3 fatty acid supplementation (4 g prescription omega-3 fatty acid concentrate) prior to low-dose endotoxin challenge
Interleukin-6 (IL-6)
90.6 pg/mL
Standard Error 14.0
99.9 pg/mL
Standard Error 14.0

Adverse Events

Placebo, Omega-3

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Omega-3, Placebo

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Penny Kris-Etherton

Pennsylvania State University

Phone: 814-863-2923

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place